Back to search

Switzerland· 70153006

Eltrombopag Devatis

A eltrombopag product containing eltrombopagum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC B02BX05

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedEltrombopag DevatisATCB02BX05REGISTER NO.70153006PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Eltrombopag is registered in 15 of 19 countries.

Countries holding a registration under ATC B02BX05 (eltrombopag), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Eltrombopag · ATC B02BX05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of eltrombopag costs, country by country.

Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.

  • Switzerland: $38.37 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Eltrombopag · price per daily dose (50 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$38.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
eltrombopagum
Manufacturer
—
Country
Switzerland (CH)
ATC code
B02BX05
ATC class
Eltrombopag
Defined daily dose
50 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680701530063
    28 Stk
    CHF 937.9

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

175 interactions on record for eltrombopag.

Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Eltrombopag · interactions on record

175 records

  • 20 severe
  • 153 moderate
  • 2 minor

Most severe, free to view

  • EluxadolineA07DA06severe
  • BerotralstatB06AC06severe
  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Eltrombopag in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All eltrombopag products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Elrevolan, Eltrombopag +pharma
  • Belgium · Eltrombopag Krka
  • Bulgaria · Eltrombopag Pharmascience, Eltrombopag Pharmdedict
  • Cyprus · Eltrombopag Msn, Eltrombopag Sandoz
  • Czechia · Eltrombopag Abdi, Eltrombopag Krka
  • Germany · Eltrombopag 1 A Pharma, Eltrombopag Abdi
  • Denmark · Eltrombopag Glenmark, Eltrombopag Krka
  • Estonia · Eltrombopag Krka, Eltrombopag Msn
  • Spain · Eltrombgopa Glenmark, Eltrombopag Aurovitas Spain
  • Finland · Eltrombopag Avansor, Eltrombopag Krka
  • France · Eltrombopag Biogaran, Eltrombopag Eg
  • United Kingdom (Northern Ireland) · Eltrombopag Abdi, Eltrombopag Accord
  • Greece · Eltrombopag Anabiosis, Eltrombopag Faran
  • Croatia · Eltrombopag Alpha-Medical, Eltrombopag Msn
  • Hungary · Elrevolan, Eltrombopag Elpen
  • Ireland · Eltrombopag Clonmel, Eltrombopag Krka
  • Iceland · Eltrombopag Accord, Eltrombopag Coripharma
  • Italy · Elrevolan, Eltrombopag Abdi
  • Liechtenstein · Eltrombopag Accord, Eltrombopag Viatris
  • Lithuania · Eltrombopag Krka, Eltrombopag Msn
  • Latvia · Eltrombopag Krka, Eltrombopag Olpha
  • Malta · Eltrombopag Aspen, Eltrombopag Clonmel
  • Netherlands · Eltrombopag Abdi, Eltrombopag Amarox
  • Norway · Eltrombopag Accord, Eltrombopag Glenmark
  • Poland · Eltrombopag Glenmark, Eltrombopag Krka
  • Portugal · Eltrombopag Bluepharma, Eltrombopag Cipla
  • Romania · Eltrombopag Dr. Reddy’s, Eltrombopag Msn
  • Sweden · Eltrombopag Anabiosis, Eltrombopag Avansor
  • Slovenia · Eltrombopag Krka, Eltrombopag Msn
  • Slovakia · Eltrombopag Glenmark, Eltrombopag Krka

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c26e22d9-e337-4881-b312-f75a8b07be0d
GET /v1/drugs/c26e22d9-e337-4881-b312-f75a8b07be0d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "eltrombopagum",
  "valid_from": "2026-08-01",
  "limitations": "[{\"description\":\"<p><strong>Immunthrombozytopenische Purpura (ITP) &ndash; Erwachsene</strong><br>Zur Behandlung von erwachsenen Patienten mit einer mindestens 6 Monate ab Diagnose dauernden (idiopathischen) immunthrombozytopenischen Purpura (ITP), die auf andere Therapieoptionen (z.B. Kortikosteroide, Immunglobuline oder Splenektomie) nicht gen&uuml;gend ansprachen, bei erh&ouml;htem Blutungsrisiko infolge ausgepr&auml;gter Thrombozytopenie. Die Behandlung soIIte abgebrochen werden, wenn nach vierw&ouml;chiger Therapie mit 75 mg/Tag die Thrombozytenwerte nicht ausreichend ansteigen.<br>Der Indikationscode dieser Limitierung ist an den Krankenversicherer zu &uuml;bermitteln.</p>\",\"costApproval\":null,\"indication\":\"22141.03\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-08-01\",\"validTo\":null},{\"description\":\"<p><strong>Immunthrombozytopenische Purpura (ITP) &ndash; Kinder ab 6 Jahren&nbsp;</strong><br>Zur Behandlung von p&auml;diatrischen Patienten (6 Jahre und &auml;lter) mit einer mindestens 6 Monate ab Diagnose dauernden (idiopathischen) immunthrombozytopenischen Purpura (ITP) und relevanter Blutungsneigung, die auf eine etablierte Behandlung (z.B. IVIG, Kortikosteroide) nicht angesprochen haben und f&uuml;r die eine Splenektomie keine Behandlungsoption dar-stellt. Dosisreduktionen bei p&auml;diatrischen Patienten m&uuml;ssen regelm&auml;ssig gepr&uuml;ft werden.<br>Der Indikationscode dieser Limitierung ist an den Krankenversicherer zu &uuml;bermitteln.</p>\\n<p>&nbsp;</p>\",\"costApproval\":null,\"indication\":\"22141.04\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-08-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 75 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2026-08-01",
  "self_retention_pct": 10
}

See everything about eltrombopag.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.